The report lists Max Healthcare Institute among the top gainers, up 3.53-4.71%.
Read this note →Max Healthcare Institute Limited
NSE MAXHEALTH BSE 543220 INE027H01010
0 filings · 0 analysed
915.00
-1.46%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 04 Nov 2026, 06:20 | long | 895.50 | 1,000.00 | 934.00 | 37% | open by 2027-11-04 |
| Mirae Asset Sharekhan | 27 Oct 2026, 16:27 | long | 835.00 | 850.00 | 851.50 | 110% | hit |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 908.00 | 1,110.00 | 934.00 | 13% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report says Max Healthcare delivered 18% EBITDA and sales growth YoY with steady occupancy, while cutting FY27/28E EBITDA estimates due to trade margin impact on oncology business.
Read this note →The report states an ADD rating on Max Healthcare.
Read this note →Under CTFT, the report notes a Buy call on Max Healthcare where profit was booked at 846.85, with listed targets of 850 and 860.
Read this note →The report lists Max Healthcare Institute among the top losers on Friday, down between 1.26-1.91%.
Read this note →The report lists Max Healthcare Institute among the top losers on 13 Oct, down 0.57-0.99%.
Read this note →The report estimates a Sales/EBITDA impact of 1.3%/5.0% from the oncology drug price cap and maintains an ADD rating.
Read this note →The report lists Max Healthcare Institute among the top losers, down 2.02-3.15%.
Read this note →The note lists Max Healthcare under short covering at 909.85 (+0.76%) with OI down 0.08%.
Read this note →The report expects 17% YoY revenue growth but margin pressure from integration of low-margin acquired hospitals, listing it as a muted performer.
Read this note →The derivatives section lists a MAXHEALTH 900 PE buy citing short build-up.
Read this note →The note lists Max Health among stocks showing weakness in the derivatives segment.
Read this note →The report expects MAXHEALTH to underperform with sales/EBITDA/PAT growth of 14%/11%/4% YoY, impacted by chemotherapy drug sales stoppage and slower occupancy ramp-up.
Read this note →The note says it estimates a ~6% EBITDA impact for Max Healthcare and maintains BUY.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief